Signaling pathways
-
BA6346 JCN037Summary: JCN037 (JGK037) is a potent, covalent inhibitor that crosses the blood-brain barrier. - BA6347 PF-6274484Summary: PF-6274484 was a potent inhibitor with s of 0.14 nM and 0.18 nM for EGFR-L858R/T790M and WT-EGFR, respectively.
- BA6348 HG-14-10-04Summary: HG-14-10-04 is a potent mutation inhibitor.
- BA6349 YK-029ASummary: YK-029A is an orally effective mutation inhibitor.
- BA6350 TAS0728Summary: TAS0728 is a potent, selective, orally active, irreversible covalent binding inhibitor of 13 nM.
- BA6351 OritinibSummary: SH-1028 is an irreversible third-generation that overcomes T790M-mediated resistance in non-small cell lung cancer.
- BA6352 PDZ1iSummary: PDZ1i is a potent, blood-brain barrier-crossing, specific inhibitor.
- BA6353 EGFR-IN-70Summary: EGFR-IN-70 is a potent inhibitor.
- BA6354 GW2974Summary: GW2974 is a potent dual inhibitor.
- BA6356 PKI-166Summary: PKI-166 is a highly potent and selective, orally bioactive inhibitor.